Buy NAD+ Injection: 10 Units Draws 10 mg, Not 10 mcg

The word injection covers all three, and almost nothing else about them is shared. What you are actually buying differs in who prepares the solution, who carries the sterility burden, and what the material costs before anyone touches it.

The fourth row is the one to strike out first. A pre-mixed NAD+ solution offered by a research supplier removes the only step you could have verified, which is what went into the liquid and when. Dry material and a stated batch is a purchase you can audit. A ready-made solution from the same channel is not.

That leaves a genuine choice between paying a clinic for the preparation and the room, or buying material and doing your own arithmetic. Our local clinic page takes the first route apart and this page takes the second.

The formats also differ by an order of magnitude in concentration, and that is worth seeing as arithmetic rather than as a vague sense that one is stronger.

Start with the vial. 1,000 mg of dry powder plus 10 mL of diluent is 100 mg/mL. A U-100 barrel graduation is 0.01 mL, so one unit holds 1 mg, 10 units holds 10 mg and a full 100 unit barrel holds 100 mg. The made-up vial is ten full barrels by volume, which is a sentence that has never once been true of a peptide vial on this site.

The last two rows are worked examples of the arithmetic, not statements about what any particular clinic prepares. They are there to show the shape of the difference: an infusion is a large volume at a low concentration delivered slowly, and a vial is a small volume at a high concentration. The same 500 mg of material sits behind either one, and at the vial rate that 500 mg costs $26.00.

Everything above is laboratory handling arithmetic for research material. Questions about amounts belong on our NAD reference page, which works its own figures from a 500 mg vial at 3 mL, or 166.7 mg/mL, and the NAD calculator will run whatever volume you enter. This page does not cover technique and does not tell you what to do with a syringe.

This is the substance of the page, so it is quoted rather than paraphrased.

On 30 October 2024 FDA published a notice reminding compounders to use ingredients suitable for sterile compounding. It states that the agency "is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products", and that ingredients "identified as food grade are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins, which can harm patients". It goes on: "FDA has received adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue with some requiring medical treatment. These reactions are consistent with excessive levels of endotoxins."

Read that carefully, because of what it is not. It is not a warning about purity, or identity, or whether the powder is really NAD+. Those are the two things a research certificate normally reports, by HPLC and mass spec, and they would both come back clean on food-grade material. Endotoxin is a separate test with a separate answer.

The regulatory machinery around that test is well established. FDA's guidance on pyrogen and endotoxins testing, updated to a second edition in March 2026, notes that the agency has accepted the Limulus Amoebocyte Lysate assay as an alternative to the rabbit pyrogen test for more than thirty years and as a finished product endotoxin test. It also makes a point worth carrying into any conversation with a supplier: there is no single universal endotoxin number. The 1987 limits table is described as out of date, and limits are calculated for the product and its route using the methods in USP chapter 85, the bacterial endotoxins test.

Which is why the format matters. The route that carries the highest exposure is the one prepared furthest from the buyer, and the material feeding it comes from the same wholesale market a research listing draws on. A supplier who publishes two identity and purity assays and no endotoxin result has answered the easy question twice.

Search for a way to buy NAD+ IV and the results split into things that are legitimately purchasable and things that only look like it.

A sterile compounded intravenous NAD+ product comes from a licensed compounder, either a pharmacy operating under section 503A of the FD&C Act or a registered outsourcing facility under 503B, and it reaches a patient through a prescriber rather than a shopping cart. That is not a channel a consumer buys from directly, and a listing that appears to offer it is not what it appears to be.

The relevant regulatory fact is more favourable to NAD+ than most compounds covered on this site, and it is routinely reported wrong. On the FDA category lists for bulk substances nominated for use in 503A compounding, updated 14 May 2026, Nicotinamide Adenine Dinucleotide (NAD) sits in category 1, bulk drug substances under evaluation. Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH) sits there too. There is no NAD entry in category 2, so any page telling you NAD+ is banned from compounding is out of date or was never right.

What category 1 means is narrow and worth stating precisely: FDA does not intend to take action against a compounder for compounding with a category 1 substance provided the conditions in the guidance are met. That is non-enforcement while an evaluation runs. It is not approval, and the list is explicitly under evaluation, so it is not permanent either. One further trap sits on the same document: Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate appears in category 3, nominated without adequate support, which is a different category for what looks like the same substance under a longer name. Our page on the legal position works through all of it.

What is straightforwardly for sale is the research listing: 1,000 mg of dry coenzyme, labelled for laboratory use, dispatched same day before the 2pm CST cut-off, at $52.00 with the code.

A dispensed product arrives with its decisions already made. A research vial arrives with none of them made, which is the honest difference between the two purchases.

The box holds one vial of lyophilised NAD+, labelled 1,000 mg, with a batch code on it and no concentration until a diluent is added. Ascension publishes two third-party assays against that listing: Kovera Labs, batch 25-05260628, tested 14 June 2026, and MZ Biolabs, batch 25-01260229, tested 26 January 2026. The first thing worth doing is matching the batch code on the certificate to the code on the vial, because a certificate for a different batch is a document about somebody else's material.

The second is reading the scope of what was tested rather than the purity headline. Identity and purity are necessary and are not the finding FDA's notice is about.

Storage is the third. Lyophilised material keeps frozen, dry and dark; once in solution it goes to refrigeration and has a limited life. Our storage guide covers the general handling and the NAD reference page carries the specific figures for this compound. Note that a gram in solution is a large amount of material sitting in a fridge against a clock, which is a real argument for choosing the diluent volume deliberately rather than by habit.

Short list, in the order that decides whether the rest matters.

• Grade. Pharmaceutical grade rather than food grade, stated by the seller rather than inferred. This is the specific failure FDA named.
• Endotoxin. A bacterial endotoxins result on the batch certificate, not identity and purity alone.
• Batch. A batch-specific certificate whose code matches the vial, from a named laboratory with a test date.
• Format. Dry powder rather than a pre-mixed solution, so the preparation is one you can account for.
• Terms. A stated refund position and a domestic return path, which our domestic supply page covers, and no human use claims anywhere on the listing.

Only after those five does the rate matter, and then it is simple: $5.20 per 100 mg with the code, $10.40 without, quoted per 100 mg because per milligram this material costs about five cents and the figure compares to nothing. The full breakdown, including what a flat shipping charge does to it, sits on the NAD+ price page.